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We investigated mechanisms of cytotoxicity induced by doxycycline (doxy) and minocycline (mino) in
the chronic myeloid leukemia K562 cell line. Doxy and mino induced cell death in exposure-dependent
manner. While annexin V/propidium iodide staining was consistent with apoptosis, the morphological
changes in Giemsa staining were more equivocal. A pancaspase inhibitor Z-VAD-FMK partially reverted
cell death morphology, but concurrently completely prevented PARP cleavage. Mitochondrial involve-
ment was detected as dissipation of mitochondrial membrane potential and cytochrome C release. DNA
double strand breaks detected with gH2AX antibody and caspase-2 activation were found early after the
treatment start, but caspase-3 activation was a late event. Decrement of Bcl-xL protein levels and
electrophoretic shift of Bcl-xL molecule were induced by both drugs. Phosphorylation of Bcl-xL at serine
62 was ruled out. Similarly, Bcr/Abl tyrosine kinase levels were decreased. Lysosomal inhibitor chloro-
quine restored Bcl-xL and Bcr/Abl protein levels and inhibited caspase-3 activation. Thus, the cytotoxicity
of doxy and mino in K562 cells is mediated by DNA damage, Bcl-xL deamidation and lysosomal degra-
dation with activation of mitochondrial pathway of apoptosis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inhibition of cell death can contribute to the resistance of
leukemic cells to chemotherapy [1]. Cell death may be divided into
distinct entities based on the morphological and biochemical fea-
tures [2]. Apoptosis may be processed through an extrinsic or
intrinsic pathway. The extrinsic pathway is initiated by extracel-
lular stressors and propagated by the trans-membrane receptors in
a caspase-dependent manner. The intrinsic apoptosis is a response
to intracellular stress such as DNA damage or oxidative stress and is
mediated by the mitochondrial outer membrane permeabilization
(MOMP) in either the caspase-dependent or -independent pathway
[2]. The loss of mitochondrial membrane potential (Djm) withcine (ECM), 6th ﬂoor, Clinical
ty Hospital Huddinge, 14186
anuchehr.abedi-valugerdi@ki.
. Hassan), zuzana.potacova@
Inc. This is an open access article usubsequent drop in ATP production is considered to be the point of
no return along the apoptotic pathway [3]. Necrosis may be un-
controlled or programmed. The former is characterized by early
loss of membrane integrity and dilation of organelles, the latter by
receptor-interacting protein kinase (RIP)-1 and RIP-3 [4]. The ly-
sosomes can contribute to any type of cell death [5].
Doxycycline (doxy) and minocycline (mino) are semi-synthetic
derivatives of tetracyclines that exhibit anti-bacterial effects and
antitumor activities in several cancer cell lines [6,7]. Doxy-induced
apoptosis was associated with loss of Djm, cytochrome C (cytC)
release, Bcl-xL inhibition, caspase activation and intracellular ROS
formation in colorectal and pancreatic cancer cell lines [6,7]. Mino-
induced apoptosis was associated with caspase-3 activation and
PARP-1 inhibition in ovarian cancer [8].
The leukemic K562 cell line established from a patient in blastic
crisis of chronic myeloid leukemia (CML) possesses characteristics
of CML [9] as cells express the p210 Bcr/Abl fusion protein and
overexpress the antiapoptotic Bcl-xL protein [10]. The aim of our
study was to assess the mechanisms of doxy- and mino-induced
cytotoxicity in K562 cells.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Chemicals and reagents
Doxycycline hyclate, minocycline hydrochloride, chloroquine
diphosphate, vinblastine sulfate and bongkrekic acid were pur-
chased from Sigma Aldrich (Stockholm, Sweden); etoposide from
Bristol-Myers Squibb (Bromma, Sweden); resazurin from R&D
systems Inc. (Minneapolis, MN, USA); Z-VAD-FMK from Bachem AG
(Bubendorf, Switzerland); cOmplete mini protease inhibitor cock-
tail from Roche AB (Stockholm, Sweden); RPMI 1640 media, Dul-
becco's phosphate-buffer saline (PBS) and fetal bovine serum (FBS)
from Invitrogen AB, (Stockholm Sweden).
2.2. Cell culture
The human myeloid HL-60 and lymphoblastic Jurkat cell lines
were purchased from DSMZ (Braunschweig, Germany), the chronic
myeloid K562 cell line from ATCC (LGC Promochem Ab, Borås,
Sweden). Cells were seeded at concentrations of 2  105 cells/ml
and cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated FBS (complete medium) at 37 C in 95% humidiﬁed 5%
CO2 atmosphere. All experiments were performed in exponentially
growing cells.
2.3. Treatment
Cells were treated with drugs in ﬁnal concentrations of
0.5e500 mg/ml in complete medium. Cells treated in 0.02% dH2O
served as controls for solvent toxicity. Cells treated with etoposide
(6 or 40 mg/ml) or vinblastine (Vb; 10 or 50 mg/ml) served as pos-
itive controls for cell death. Cells incubated in complete media
served as controls.
Cells were treated with pan-caspase inhibitor Z-VAD-FMK in a
concentration of 100 mM for 1 h. Then doxy orminowere added in a
ﬁnal concentration of 50 mg/ml and cells were incubated for 6, 24
and 48 h. Fresh Z-VAD-FMK was added to the cultures every 24 h.
Cells were incubated with the adenine nucleotide (ADP/ATP)
translocator (ANT) inhibitor bongkrekic acid (BKA) in a ﬁnal con-
centration of 100 mM for 4 h and then treated concomitantly with
BKA (50 mM) and doxy or mino (50 mg/ml) for 48 h.
Cells were treatedwith the lysosomal inhibitor chloroquine (CQ)
in ﬁnal concentrations of 25 or 50 mM for 1 h followed by treatment
with doxy or mino in concentrations of 50 mg/ml for 48 h.
2.4. Cell viability assay
Ten thousands cells per well were seeded in triplicate on 96
wells black microplates and incubated with doxy or mino
(0.5e500 mg/ml) for 24 h. Then resazurin was added in a ﬁnal
concentration of 10% and cells were further incubated for 2 h at
37 C. Fluorescence was read using FLUOstar Optima (BMG Labtech
GmbH, Offenburg, Germany) at awavelength of 590 nm. Viability of
treated cells was expressed as a percentage of the viability of
controls. The 50% inhibitory concentration (IC50) was calculated as
the drug concentration inducing 50% reduction in cell viability
using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
2.5. Assessment of cell death
100,000 cells were stained with annexin V (Becton Dickinson
(BD), San Jose, CA, USA) in a concentration of 125 ng/ml and pro-
pidium iodide (PI) (Sigma Aldrich, Stockholm, Sweden) in a con-
centration of 5 mg/ml in 100 ml of annexin V binding buffer for
15 min at room temperature (RT) in the dark. Samples wereanalyzed using FACScan ﬂow cytometer, CELL Quest software (BD)
and free Flowing Software ver. 2.5.1 (created by Perttu Terho, Cell
Imaging Core, Turku Centre for Biotechnology, Finland, http://
www.ﬂowingsoftware.com/).
Cell death morphology consistent with apoptosis (condensed
chromatin and fragmented nuclei) or necrosis (increased cell size
and loss of cellular architecture) was assessed using May-Grün-
wald-Giemsa staining on cytospun slides and expressed as a per-
centage of a minimum of 400 cells counted per slide.
2.6. Assessment of mitochondrial membrane potential (Djm)
Cells were incubated with the mitochondrial probe tetrame-
thylrhodamine methyl ester (TMRM) (Molecular Probes, Carlsbad,
CA, USA) in a ﬁnal concentration of 25 nM in PBS for 30min at 37 C.
After washing, cells were re-suspended in PBS and analyzed using
ﬂow cytometry.
2.7. Western blot (WB) analysis
Cells were lysed in Tris-NaCl buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 25 mM EDTA, 1 mM NaF, cOmplete mini protease inhibitor
cocktail, 1 mM PMSF and 1% Triton  100) on ice for 30 min, then
centrifuged at 10,000 g for 10 min at 4 C.
To assess poly (ADP-Ribose) polymerase (PARP), cells were
incubated in PARP extraction buffer (62.5 mM Tris pH 6.8, 6 M urea,
2% SDS, 10% Glycerol and 0.001% bromophenol blue) for 15 min at
RT, then for another 5 min at 95 C.
For subcellular fractionation, the cells were incubated in
digitonin cytosolic buffer (5 mM TriseHCl pH 7.4, 5 mM succinic
acid pH 6.3, 10 mM MgCl2.6H2O, 0.5 mM EDTA, 147.5 mM KCl,
5 mM KH2PO4 and 0.005% digitonin) for 30 min on ice and then
centrifuged at 10,000 g for 10 min at 4 C. The supernatant
(cytosolic fraction) was collected and the pellet was re-
suspended in PBS containing cOmplete mini protease inhibitor
(pellet fraction).
Protein concentrations were assessed using Pierce® BCA or
660 nm® protein assay kits (Pierce, Rockford, IL, USA) according the
manufacturer's recommendations.
For protein separation, equal volumes of samples and 2х
Laemmli buffer supplemented with 5% 2-mercaptoethanol were
boiled for 5 min at 95 C. Protein samples (10 or 20 mg) were
separated on 12 or 15% SDS-PAGE and transferred to a PVDF or to
nitrocellulose membranes, whichever appropriate. The mem-
branes were blocked in 5% non-fat dry milk solution for 2 h at RT
and incubated overnight with primary antibodies
(Supplementary Table 1) at 4 C. Then the membranes were
rinsed and incubated with secondary antibodies conjugated with
peroxidase (Amersham Pharmacia Biotech AB, Uppsala, Sweden)
or IRDye®800CW or IRDye®680CW (LI-COR, Lincoln, NE, USA) for
1 h at RT. The proteins were visualized using SuperSignal West
Pico Chemiluminescent substrate (Pierce) or ODYSSEY imaging
system (LI-COR). Actin was used as a marker of equal protein
loading.
2.8. Assessment of intracellular reactive oxygen species (ROS)
The intracellular ROS levels were assessed using OxiSelect™
Intracellular ROS assay Kit with green ﬂuorescence (Cell Biolabs,
San Diego, CA, USA). Following the treatment with doxy or mino,
cells were incubated with 100 mM of 20-70-dichlorodihydro-
ﬂuorescin (DCFH-DA) in media for 1 h at 37 C. Then the cells were
washed in PBS and the DCF ﬂuorescence measured using FLUOstar
Optima at wavelengths 485/520 nm.
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Experiments were performed three times independently and
the results are expressed as a mean ± SD wherever appropriate.
3. Results and discussion
3.1. Effect of TCNAs on viability of leukemic cell lines
Incubation of the human leukemic cell lines with doxy andmino
for 24 h reduced the cell viability with the IC50ies presented in
Table 1.
Antitumor effects of doxy and mino have been reported in
several cancer cell lines with IC50ies between 10 and 30 mg/ml
[7,8,11], but no genotoxic or cytotoxic effects were observed in
lymphocytes [12]. Tolemeo et al. reported IC50 of doxy in HL-60
cells to be 8 mg/ml [13]. In our study, IC50ies of doxy and mino are
in close agreement with the reported IC50ies. The K562 cell line
possesses the Bcr/Abl tyrosine kinase fusion protein and therefore
has been selected for further experiments. For studies on cytotox-
icity mechanisms, we selected drug concentrations up to 50 mg/ml
to strengthen the cytotoxic effects. In the following sections, drug
concentrations of 50 mg/ml are reported if not stated otherwise.
3.2. Cell death
Doxy and mino induced cell death in an exposure-dependent
manner as detected with annexin V and PI positivity (Fig. 1). In-
crease of annexin Vþ and annexin Vþ/PIþ cells was accompanied
by a shift to smaller and more granular cells consistent with
apoptosis. Morphological changes consistent with cell death were
detectable at 6 h and 24 h of incubation with doxy and mino,
respectively. However, morphology was equivocal and the type of
cell death could not be determined using morphological criteria.
Surprisingly, lower concentrations of doxy and mino (10 and
20 mg/ml) did not increase cell death compared to controls until
48 h of incubation. Considering the determined IC50ies, greater ef-
fect was expected from a concentration of 20 mg/ml. The difference
may be explained by fundamental differences between the
methods. Annexin V/PI assesses features of individual dying cells,
while the resazurin assay determines the metabolism of total cell
mass. Morphological staining corroborated the levels of the total
cell death from Annexin V/PI assay (Supplementary Figure 1).
3.3. Caspase activation in TCNAs-induced cell death
Activation of caspase-2, -3, -8 and -9 was observed after treat-
ment with both doxy and mino. The 12 kDa fragment of caspase-2
was detected at 6 h after start of treatment. Further incubation
resulted in a reduction and at 48 h total disappearance of the
48 kDa procaspase bands in cells treated with doxy and mino in
concentrations of 50 mg/ml (Fig. 2A). The early caspase-2 activation
was conﬁrmed by detecting the caspase-2 intermediate fragment ofTable 1
IC50 of doxy and mino in the human leukemic cell lines.
Doxy Mino
IC50
(mg/ml)
95% CI R2 IC50
(mg/ml)
95% CI R2
HL60 9.2 8.79e9.66 0.995 9.9 8.61e11.29 0.974
Jurkat 13.8 12.34e15.43 0.979 24.7 21.69e28.08 0.972
K562 33.9 28.7e40.1 0.882 23.4 19.77e27.79 0.89
CI ¼ conﬁdence interval.32 kDa at 6 h after incubation start using another caspase-2 anti-
body (Fig. 2B). Furthermore, the caspase-2 active fragment of
18 kDawas detected in the cytosolic fraction of doxy treated cells at
6 and 24 h after the start of incubation (Fig. 2C). Caspase-2 func-
tions as an initiator as well as effector caspase [14]. Caspase-2 is
located in the nucleus, Golgi complex and soluble cytoplasm. It is
activated in response to cellular stress, such as DNA damage or
oxidative stress [15]. In our study, only minor increase in the ROS
levels was found, but DNA double strand breaks were detected.
Thus, most likely, caspase-2 was activated in response to DNA
damage.
The 23 kDa fragment of caspase-8 was detected at 24 h of in-
cubation with both drugs. The 19 kDa and 15 kDa fragments of
caspase-3 and the 37 kDa fragment of caspase-9 were ﬁrst detected
in cells treated with doxy for 24 h and with mino for 48 h
(Supplementary Figure 2). Altogether, the cell death induced by
both drugs is caspase-mediated.3.4. PARP-1 and Z-VAD-FMK in TCNAs-induced cell death
The 85 kDa fragment of PARP-1 was detected at 48 h after the
incubation start with doxy and mino. Pretreatment with the pan-
caspase inhibitor Z-VAD-FMK effectively prevented PARP-1 cleav-
age (Supplementary Figure 3A). Moreover, Z-VAD-FMK reduced the
doxy- andmino-induced cell deathmorphology at 24 and 48 h after
the start of incubation. Cells with apoptosis-like features decreased
more than cells with necrotic features. A slight shift in cell
appearance from apoptosis-like morphology towards cellular
swelling was observed. This shift was most distinct in cells treated
concomitantly with doxy and Z-VAD-FMK (Supplementary
Figure 3B).
We assessed the effect of 25 or 50 mM necrostatin-1 on TCNAs
induced cell death, but the total cell death was not affected by
necrostatin-1. These results further indicated involvement of
apoptotic mechanisms in TCNAs-induced cell death.3.5. TCNAs effect on the mitochondria
Translocation of cytC to cytosol was observed at 6 h after in-
cubation start with doxy and mino. The release of cytC was not
associated with Bax or BID activation as the 16 kDa and 18 kDa
fragments of Bax and BID were not observed before 48 and 24 h,
respectively. Nevertheless, the role of BID in cytC release could not
be completely ruled out since the BID has been reported to possess
proapoptotic activity even without cleavage of the molecule [16].
Doxy- and mino-induced loss of Djmwas ﬁrst observed at 12 h
of incubation and progressed in a concentration- and incubation
time-dependent manner. The loss of Djm is a cardinal feature of
the mitochondrial pathway of apoptosis and is potentiated by
opening of the permeability transition pore (PTP) [17]. PTP spans
through both the inner and the outer mitochondrial membranes. It
consists of the adenine-nucleotide translocator (ANT) in the inner
and a voltage-dependent anion channel (VDAC) in the outer
mitochondrial membrane. Cyclophilin D is inside the mitochondria
[18]. In our study, pre-incubation of K562 cells with the PTP in-
hibitor BKA did not reduce the loss of Djm induced by doxy or
mino. This result indicates that either the loss of Djm wasn't
dependent on the PTP opening or the loss of Djm relied on the
VDAC opening without contribution of other components (ANT/
cyD) [19]. The VDAC is considered to be the core component of the
PTP. Bcl-xL and Bax interact with the VDAC channel and the Bax to
Bcl-xL ratio controls the degree of the opening [20]. In our study,
doxy and mino induced reduction of the Bcl-xL protein levels that
might facilitate the Bax-VDAC interaction.
Fig. 1. TCNAs-induced cytotoxicity in K562 cells. Cells were incubated with doxy or mino (10, 20 and 50 mg/ml) for 6, 24 and 48 h. Cells were stained with annexin V/PI and analyzed
using ﬂow cytometry. Cell subpopulations were estimated as a percentage of 10,000 events. The results are expressed as mean ± SD of three independent experiments.
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and DNA damage
Doxy affected the expression of the Bcl-xL protein. The full-
length 26 kDa protein band was reduced at 24 h and almost dis-
appeared at 48 h after the incubation start. Mino-induced effect on
the Bcl-xL protein level was similar, but less pronounced compared
to doxy (Fig. 3A). We corroborated the ﬁnding by another Bcl-xL
antibody (clone 54H6) (Fig. 3B). This antibody detects Bcl-xL as
two bands, 32/33 kDa and 30 kDa, respectively. Besides the
decrease of Bcl-xL protein levels, doxy andmino induced changes in
the electrophoretic mobility of the Bcl-xL molecule. The expression
of the 32/33 kDa band increased at 6 h of incubation with doxy and
mino compared to the controls. At later time points, the levels ofFig. 2. Caspase-2 activation in TCNAs treated cells. Cells were incubated with doxy or mino
served as positive controls, cells in complete medium as controls. Proteins were analyzed
cytosolic fraction.the Bcl-xL decreased in an incubation time-dependent manner
(Fig. 3B).
The 32/33 kDa band was reported to be a result of the Bcl-xL
phosphorylation or deamidation and was associated with loss of
the antiapoptotic effect. The Bcl-xL molecule is predominantly
phosphorylated on Serine 62, while phosphorylation on other sites
is less likely [21]. The Bcl-xL molecule contains two labile aspar-
aginyl sites at positions 52 and 66 which are prone to deamidation
in response to cellular stress such as DNA damage or oxidative
stress [22].
In order to identify the modiﬁcation of the Bcl-xL molecule, we
used etoposide as a control for deamidation and vinblastine as a
control for Serine 62 phosphorylation. We could not demonstrate
phosphorylation of Bcl-xL at Serine 62 using a speciﬁc antibody (p-(10, 20 and 50 mg/ml) for up to 48 h. Cells incubated with etoposide (6 and 40 mg/ml)
using Western blot. (A) Caspase-2 (C2). (B) Caspase-2 (11B4). (C) Caspase-2 (11B4) in
Fig. 3. The effect of TCNAs on Bcl-xL and DNA. Cells were incubated with doxy and mino (10, 20 and 50 mg/ml) for 6, 24 and 48 h. Etoposide (6 and 40 mg/ml) and vinblastine (10 or
50 mg/ml) served as positive controls for Bcl-xL deamidation and phosphorylation at serine 62, respectively. Cells incubated in complete media served as control. Proteins were
detected using Western blot. (A) Bcl-xL, (B) Bcl-xL (54H6), (C) phospho-Bcl-xL pSer62, (D) gH2Ax, (E) NHE-1 antiporter.
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observed with any of the antibodies. Thus, the Bcl-xL molecule is
modiﬁed by early deamidation followed by decreased protein
levels.
Bcl-xL levels are continuously modulated by deamidation that
reduces cellular activities of Bcl-xL and targets Bcl-xL for degra-
dation [23]. DNA damage enhances Bcl-xL deamidation that is
mediated by increased protein expression of the NHE-1 antiporter
and intracellular alkalinization [24]. However, in myeloid cells from
patients with CML expressing Bcr/Abl fusion protein, DNA damage
did not induce either an increase in protein levels of the NHE-1 or
increase in intracellular pH, nor Bcl-xL deamidation and apoptosis[25]. In myeloproliferative disorders, the oncogenic tyrosine ki-
nases contributed to resistance to etoposide by suppression of Bcl-
xL deamidation and the levels of Bcr/Abl protein correlated with
the degree of inhibition of the Bcl-xL deamidation pathway [25].
In our study, DNA double strand breaks were detected as 15 kDa
band of gH2AX at 6 h after the incubation start with doxy andmino
(Fig. 3D). However, the levels of NHE-1 antiporter protein were not
increased at 6 h after the incubation start, and at later time points
the levels were reduced (Fig. 3E). The oxidative stress is considered
to be a favorable condition for Bcl-xL deamidation by a mechanism
that is not dependent on the increased NHE-1 activity [26]. How-
ever, in our study, no signiﬁcant increase of the ROS levels was
Fig. 4. The role of lysosomal inhibitor chloroquine in TCNAs cytotoxicity. Cells pre-
incubated with CQ (25 or 50 mM) for 1 h were treated with doxy and mino (50 mg/ml)
for 24 and 48 h. Etoposide (40 mg/ml) served as a positive control. Cells incubated in
complete media served as a control. Protein expression was assessed using Western
blot. (A) Bcl-xL, (B) caspase-3, (C) Bcr/Abl detected with antibody against Bcr.
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intracellular pH in K562 cells has been reported to be signiﬁcantly
higher than in peripheral blood mononuclear cells and bone
marrow cells [27].
Moreover, Bcr/Abl tyrosine kinase has been shown to inhibit the
proapoptotic Bcl-xL deamidation pathway [25]. Thus, treatment
that restores Bcl-xL deamidation pathway may overcome the Bcr/
Abl resistance.
3.7. Effect of lysosomal inhibitor chloroquine
Co-incubation of drugs with CQ restored the Bcl-xL protein level
(Fig. 4A) and inhibited caspase-3 activation (Fig. 4B). Furthermore,
TCNAs treatment was associated with changes in the protein levels
of the tyrosine kinases Bcr/Abl P210. A reduction in the protein
levels of Bcr/Abl at 48 h after incubation start was reversed by CQ
(Fig. 4C).
The lysosomal contribution to the induction of apoptosis is well
established [5]. Induction of lysosomal membrane permeabiliza-
tion (LMP) facilitates the release of lysosomal enzymes and protons
that reduce the cytoplasmic pH, which facilitates caspase activation
[28]. In the present study, we did not measure the cytoplasmic pH,
but a reduction in NHE-1 antiport protein was observed (Fig. 3E).
This ﬁnding may imply intracellular acidiﬁcation [29]. The lyso-
somal pH is 4.3 ± 0.3 [28]. Doxy and mino have dissociation con-
stants (pKa) of 3.5, 7.7 and 9.5 and 2.8, 5.0, 7.8 and 9.3, respectively
[26]. The isoelectric point is 5.0 for doxy and 6.4 for mino [30,31].
Thus, lysosomesmay also be considered as a cellular target for doxy
and mino as has been suggested by other authors [32,33].
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